Nippon Shinyaku Deal History & Licensing Activity
Nippon Shinyaku is a mid-size pharma headquartered in Sweden. Over the past three years, Nippon Shinyaku has been involved in 4 licensing and acquisition transactions, with a primary focus on Other (4 deals). The company currently has 12 active clinical trials, primarily in Rare Disease.
Deals (12mo)
2
Active Trials
12
Top Modality
Other
Focus Area
Rare Disease
Nippon Shinyaku Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Nippon Shinyaku in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Tadekinig alfa | AB2 Bio | Other | Phase 3 | option | Jul 30, 2026 |
| EXG-7001 | Elixirgen Therapeutics | Other | Preclinical | option | Jun 26, 2026 |
Nippon Shinyaku Pipeline Focus
Therapeutic areas and modalities where Nippon Shinyaku is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Nippon Shinyaku Strategic Signals
Key indicators of Nippon Shinyaku's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Nippon Shinyaku Clinical Pipeline
Nippon Shinyaku has 12 active clinical trials across 3 development phases.
4
Phase 1
6
Phase 2
2
Phase 3
See How Your Asset Matches Nippon Shinyaku's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Nippon Shinyaku Licensing & Deal Activity
Nippon Shinyaku is a mid-size pharma company based in Sweden that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Nippon Shinyaku ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Nippon Shinyaku include Rare Disease (5 deals and trials), Rare Disease (3 deals and trials), Musculoskeletal (2 deals and trials), and Cardiovascular (2 deals and trials). In terms of modality, Nippon Shinyaku has shown particular interest in other, gene therapy, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Nippon Shinyaku and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Nippon Shinyaku's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.